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ndothelial Dysfunction
ssociated With
rug-Eluting Stents
hat, Where, When, and How?*
oseph B. Muhlestein, MD, FACC
urray, Utah
he advent of drug-eluting stents (DES) into the practice of
nterventional cardiology has had a tremendous impact. After
heir demonstration of a significant reduction in restenosis in
andomized trials and U.S. Food and Drug Administration
pproval for their use in 2003, the incorporation of DES into
linical practice was rapid and extensive. However, beginning
n 2004, a variety of reports began to circulate documenting an
ncreased incidence of early, late, and very late stent thrombosis
fter DES implantation, especially after discontinuation of
ual antiplatelet therapy (1). This was proposed to be caused by
mpaired endothelialization of the vessel at the site of stent
eployment because of the presence of either the drug, the
tent polymer, or both (2). Shortly thereafter, several studies
eported another, more distant, effect of both sirolimus-coated
See pages 2123 and 2130
nd paclitaxel-coated stents, that of long-term endothelium-
elated vascular dysfunction detected in nonstented segments
f the coronary artery (3–6). Although the precise mechanism
f this distant vascular phenomenon was not known, because it
as not apparent in vessels receiving bare-metal stents (BMS),
t was presumed to be secondary to the presence of either the
ntiproliferative drug itself or its associated polymeric DES
oating. Two important articles published in this issue of the
ournal address these issues. One evaluates the effect on
ascular function of chronic exposure to sirolimus (7). The
ther reports the results of a new DES, with both a different
rug and a different polymeric coating, that does not seem to
nduce endothelial dysfunction (8). Although neither study
ompletely answers all possible questions regarding this issue,
hey both contribute to our understanding of the underlying
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, Intermountain Medical Center, Murray, Utah.S
r. Muhlestein has received research funds from Boston Scientific and Cordis
orporations in relationship to stent research.athophysiology of the process and offer hope for a resolution
f the problems with next-generation DES.
In the article by Jabs et al. (7), a 7-day continuous infusion
f sirolimus into Wistar rats produced a marked degree of
ndothelial dysfunction as well as a desensitization of the
ndothelium-independent vasodilator nitroglycerin, showing
hat the drug may play a specific role. The investigators also
eported a possible mechanism, that of sirolimus increasing the
roduction of vascular superoxide, with the result being a loss
f vascular nitric oxide bioavailability. Although their rat model
as one of prolonged systemic exposure to sirolimus, they
roposed that these processes could contribute to the observed
ndothelial dysfunction noted after deployment of sirolimus-
oated stents. There are several other important limitations to
his study. First, it is not certain whether the sirolimus dosing
n the rat study is comparable at the vascular level to that of a
oronary artery containing a DES. Second, in the rat model,
he presence of sirolimus adversely affected both endothelium-
ependent and endothelium-independent vascular function.
n the clinical studies of DES, it was only the endothelium-
ependent vascular function that was adversely affected.
hird, the hypothesis that it is the effect of the sirolimus that
esults in long-term endothelial dysfunction must be con-
rasted with the fact that vascular dysfunction after sirolimus-
luting stent deployment has been reported long after the drug
s gone. If the drug is still the cause, this implies that its effect
ust persist beyond drug exposure. In the rat model, the
xposure of sirolimus continued to the end of the study, so we
annot tell whether endothelial dysfunction was persistent or
ot. Therefore, although the drug may play some role, it is still
ossible that the polymer may also be important.
Both the sirolimus-coated Cypher (Cordis Corporation,
iami Lakes, Florida) and paclitaxel-coated Taxus DES
Boston Scientific Corporation, Natick, Massachusetts) have
imilar permanent, nonbioabsorbing polymer coatings, includ-
ng poly-n-butyl methacrylate plus polyethylene-vinyl acetate for
ypher and poly [styrene-isobutyl-styrene] for Taxus (9). These
olymer layers are used both as drug reservoirs and as nondrug
op-coated films to achieve optimal drug release kinetics. Both
ave been shown to produce, in some patients, a hypersensitivity
esponse that could contribute to downstream vascular dysfunc-
ion (2). In the article byHamilos et al. (8), the investigators report
he results of a second-generation DES with a bioabsorbable
olymer that may eliminate the endothelial dysfunction produced
y earlier stent designs. In this clinical study evaluating the new
obori biolimus A9-eluting stent (Terumo Corporation, Tokyo,
apan), vascular reactivity at 9 months was preserved in the
iolimus stent when compared with the Cypher stent. The
obori stent is different from the Cypher stent in several ways.
irst, it has a different drug, biolimus A9, which is apparently
ore lipophilic and binds more rapidly to its tissue target. This
ay assist in limiting the drug’s presence strictly to the stent
eployment site, thereby preventing its spread to more distant
ascular sites where it might contribute to vascular dysfunction.
econd, the drug is placed only on the vessel side of the stent, thus
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Editorial Comment June 3, 2008:2139–40educing the amount of drug released into the peripheral circula-
ion and potentially minimizing any distant drug effect. Third, the
iolimus stent has different drug-release kinetics, which may
educe the magnitude of exposure of the drug to surrounding
issues at any given time. Fourth, the Nobori stent coating itself is
ot permanent and is expected to be absorbed within a few
onths, leaving a simple BMS remaining. Which of these
ifferences between the Nobori and Cypher stents is most impor-
ant to the present study’s findings related to long-term vascular
unction is not known, but it is certainly possible that timely
esorption of the polymer is critical to the maintenance of
ong-term healthy vascular function.
Regardless of the mechanisms of the reduction of vascular
unction after DES deployment, the following questions re-
ain: what is the clinical relevance of this finding and what can
e done about it? Certainly, in many circumstances, reduced
ndothelial function has been shown to correlate with in-
reased atherogenesis, as well as cardiovascular risk (10).
hether DES-induced endothelial dysfunction produces a
imilar risk is not known. However, one disappointing finding
n most long-term follow-up studies comparing the use of
ES with BMS is the general lack of improvement in the hard
utcomes of death and myocardial infarction (11). Indeed in
everal studies, the risk of death is increased with the use of
ES over and above what might be expected from the
ocumented risk of stent thrombosis (12). It is possible that an
ncreased cardiovascular risk from DES-associated endothelial
ysfunction may help to explain these findings. In addition, it
s not yet known how generalized the effect of DES-induced
ndothelial dysfunction is. Most published studies have only
ooked at the target vessel. In the present study by Hamilos et
l. (8), endothelial dysfunction was noted in the target vessel
oth proximal as well as distal to the site of Cypher stent
eployment. This implies that the effect did not require a
ownstream relationship to have an impact. Although this has
ot yet been studied, it does seem possible that DES-
ssociated endothelial dysfunction may be generalized to other
oronary arteries aside from the specific one where the DES
as placed. If this is the case, then much of the potential
linical benefit from presently available DES, occurring as a
esult of a reduced incidence of in-stent restenosis, might be
ffset by the adverse clinical effects of DES-associated endo-
helial dysfunction.
Finally, if DES-associated endothelial dysfunction is a real
nd harmful phenomenon, what can be done about it? As
hown in this issue of the Journal, newer, perhaps better,
econd-generation DES are presently being designed and
ested that may eliminate this adverse effect. However, in the
eantime, for the millions of patients in whom first-
eneration DES have already been deployed, aggressive efforts
o improve general endothelial function could be helpful.
ggressive lipid management with statins has been shown to
mprove vascular reactivity (13). Other lipid therapies such as
iacin and fibrates also may contribute (14,15). The recently
eleased highly selective beta-1 receptor antagonist nebivolol
as also been shown to improve vascular function, potentiallyhrough a nitric oxide–mediated mechanism (16). All of these
pproaches may mitigate against the possible adverse clinical
ffects of DES-associated vascular dysfunction.
In summary, DES-associated endothelial dysfunction
eems to be a real and potentially significant, fascinating,
nd unexpected phenomenon. Further research, such as
eported in the 2 articles presented in this issue of the
ournal (7,8), is needed to gain a fuller understanding of its
linical relevance.
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